

ASX Release

SUDA APPOINTS DAVID PHILLIPS TO THE BOARD

PERTH, AUSTRALIA – 9 April 2018: SUDA Pharmaceuticals Ltd (ASX: SUD), a leader in oromucosal drug delivery, has appointed David Phillips to the Board as a non-executive Director, effective 6 April 2018.

David was previously appointed as an advisor to the Board as announced on 28 November 2017. The addition of David as a non-executive Director provides the Board with further pharmaceutical industry and capital markets experience as the Company transitions through the next stage of its growth.

David has over 30 years of experience in the global healthcare industry, including 14 years in sales and marketing with Glaxo Wellcome, Cephalon Inc, Oxford Molecular Group Plc, and eight years with SR One (GlaxoSmithKline's corporate venture fund).

David spent 12 years at Board level as Chief Business Officer of Argenta Discovery, The Automation Partnership and BioFocus PLC. David re-joined GlaxoSmithKline's (GSK) SR One corporate venture arm in 2008 to pioneer a new function to incubate and spin-out technologies from GSK and in parallel investing in early-stage life science companies.

He has been involved in the monetisation of a number of R&D operations and drug delivery technologies, including leading the team that divested GSK's opiates business in Australia in 2015. David was, previously, a senior investment manager at BioScience Managers Pty Ltd, a leading life sciences investment firm.

SUDA's CEO, Mr Stephen Carter, commented: "We have been working with David Phillips over the last few months and have found his input to the board to be very considered and relevant and we are delighted that David has now joined the Board. It is a timely appointment as we continue to grow the business and David will bring a wealth of experience to assist us in this new growth phase."



Further information:
STEPHEN CARTER
CHIEF EXECUTIVE OFFICER / MANAGING DIRECTOR
SUDA Pharmaceuticals Ltd
Tel: +61 8 6142 555
sjcarter@sudapharma.com

NOTES TO EDITORS:

About SUDA Pharmaceuticals Ltd

SUDA Pharmaceuticals Ltd (ASX: SUD) is a drug delivery company focused on oro-mucosal administration, headquartered in Perth, Western Australia. The Company is developing low-risk oral sprays using its OroMist® technology to reformulate existing pharmaceuticals. The many potential benefits of administering drugs through the oral mucosa (i.e.: cheeks, tongue, gums and palate) include ease of use, lower dosage, reduced side effects and faster response time. SUDA's product pipeline includes ZolpiMist™, a first-in-class oral spray of zolpidem for insomnia. ZolpiMist is marketed in the USA and SUDA has rights to the product outside of the US and Canada. SUDA has submitted a Marketing Authorisation Application to the Australian Therapeutic Goods Administration for ArTiMist®, its novel sublingual malaria treatment for children. In a Phase III trial, ArTiMist was shown to be superior to intravenous quinine. Other products in development include oral sprays for the treatment of migraine headache, chemotherapy-induced nausea and vomiting, erectile dysfunction, PAH, epileptic seizures and pre-procedural anxiety. For more information, visit www.sudapharma.com